专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08524735B2 Aerosolized fluoroquinolones and uses thereof 有权
标题翻译：气雾化氟喹诺酮类及其用途
公开(公告)号：US08524735B2
公开(公告)日：2013-09-03
申请号：US12604347
申请日：2009-10-22
申请人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Lomovskaya , David C. Griffith
发明人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Lomovskaya , David C. Griffith
IPC分类号： A61K31/00 , A61K31/44 , A61K31/4412 , A61K33/00 , A61K33/06 , A61K33/14 , A61K33/26 , A61K33/30 , A01N25/00 , A01N25/02 , A01N25/06 , A01N59/08
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
摘要翻译：本文公开了适用于气雾化和使用这种制剂的氟喹诺酮类制剂用于气雾剂施用氟喹诺酮抗微生物剂以治疗肺细菌感染。特别地，描述了专门配制并递送用于肺细菌感染的吸入性左氧氟沙星。方法包括用于生产和使用所述组合物的吸入方案和制造方法。

2. 发明申请

US20100166673A1 AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF 有权
公开(公告)号：US20100166673A1
公开(公告)日：2010-07-01
申请号：US12604340
申请日：2009-10-22
申请人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Lomovskaya , David C. Griffith
发明人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Lomovskaya , David C. Griffith
IPC分类号： A61K9/12 , A61P31/04
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

3. 发明申请

US20100087416A1 AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS 有权
标题翻译：用于改进药物动力学的气溶胶氟喹诺酮配方
公开(公告)号：US20100087416A1
公开(公告)日：2010-04-08
申请号：US12574680
申请日：2009-10-06
申请人： David C. Griffith , Michael N. Dudley , Mark W. Surber , Keith A. Bostian , Olga Rodny
发明人： David C. Griffith , Michael N. Dudley , Mark W. Surber , Keith A. Bostian , Olga Rodny
IPC分类号： A61K31/397 , A61K31/535 , A61P11/06 , A61P11/00
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
摘要翻译：本发明涉及抗微生物剂领域。特别地，本发明涉及用二价或三价阳离子配制的雾化氟喹诺酮类药物，并且具有改善的肺可用性，用于治疗和管理肺和上呼吸道的细菌感染。

4. 发明授权

US08546423B2 Aerosolized fluoroquinolones and uses thereof 有权
公开(公告)号：US08546423B2
公开(公告)日：2013-10-01
申请号：US12604340
申请日：2009-10-22
申请人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Lomovskaya , David C. Griffith
发明人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Lomovskaya , David C. Griffith
IPC分类号： A61K31/00 , A61K31/44 , A61K31/4412 , A61K33/00 , A61K33/14 , A61K33/26 , A61K33/30 , A01N25/00 , A01N25/02 , A01N25/06 , A01N59/08
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

5. 发明授权

US08357696B2 Aerosolized fluoroquinolones and uses thereof 有权
公开(公告)号：US08357696B2
公开(公告)日：2013-01-22
申请号：US12695981
申请日：2010-01-28
申请人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Rodny , David C. Griffith
发明人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Rodny , David C. Griffith
IPC分类号： A61K9/14 , A61K31/00 , A61K31/44 , A61K31/4412 , A61K33/00 , A61K33/06 , A61K33/14 , A61K33/26 , A61K33/30 , A01N25/00 , A01N25/02 , A01N25/06 , A01N59/08
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

6. 发明申请

US20100152098A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF 失效
标题翻译：多巴酚丁醚泵抑制剂及其治疗用途
公开(公告)号：US20100152098A1
公开(公告)日：2010-06-17
申请号：US12613329
申请日：2009-11-05
申请人： Tomasz Glinka , Olga Rodny , Keith A. Bostian , David M. Wallace , Robert I. Higuchi , Chun Chow , Chi Ching Mak , Gavin Hirst , Brian Eastman
发明人： Tomasz Glinka , Olga Rodny , Keith A. Bostian , David M. Wallace , Robert I. Higuchi , Chun Chow , Chi Ching Mak , Gavin Hirst , Brian Eastman
IPC分类号： A61K38/05 , A61K38/02 , C07D265/30 , C07D241/42 , C07D215/38 , C07D211/58 , C07D211/06 , C07D213/643 , C07D213/74 , C07D231/12 , C07D209/20 , C07D207/14 , C07D333/24 , C07D321/10 , C07D319/18 , C07D309/10 , C07D307/79 , C07C311/46 , C07C237/20 , A61P31/08 , A61P31/06 , A61P31/04 , C07D217/22 , A61K31/472
CPC分类号： C07K5/06086 , A61K38/00 , C07K5/06104 , C07K5/06113 , C07K5/06139 , C07K5/06191 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.
摘要翻译：公开了具有多碱性官能团的化合物。该化合物抑制细菌外排泵抑制剂，并与抗菌剂组合使用以治疗或预防细菌感染。这些组合可以有效地抵抗通过外排泵机制对抗细菌剂产生抗性的细菌感染。

7. 发明申请

US20120237564A1 Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease 审中-公开
标题翻译：使用气溶胶抗生素治疗慢性阻塞性肺疾病
公开(公告)号：US20120237564A1
公开(公告)日：2012-09-20
申请号：US13398310
申请日：2012-02-16
申请人： Michael N. Dudley , Neil Berkley , David C. Griffith , Jeffery S. Loutit , Elizabeth E. Morgan , Keith A. Bostian , Sanjay Sethi
发明人： Michael N. Dudley , Neil Berkley , David C. Griffith , Jeffery S. Loutit , Elizabeth E. Morgan , Keith A. Bostian , Sanjay Sethi
IPC分类号： A61K31/5383 , A61K9/14 , A61P11/08 , A61K31/56 , A61P11/00 , A61P31/04
CPC分类号： A61K31/496 , A61K9/0078
摘要： The present invention relates to methods and compositions for treating obstructive pulmonary disorders. In particular, compositions and methods described herein relate to the use of an aerosolized antibiotic for treating obstructive pulmonary disorders including chronic obstructive pulmonary disorder (COPD) and chronic bronchitis (CB).
摘要翻译：本发明涉及用于治疗阻塞性肺病的方法和组合物。特别地，本文所述的组合物和方法涉及气雾化抗生素用于治疗阻塞性肺病，包括慢性阻塞性肺病（COPD）和慢性支气管炎（CB）的用途。

8. 发明授权

US5324659A Yeast mutants useful for indentifying immunosupressants 失效
标题翻译：酵母突变体可用于鉴定免疫抑制剂
公开(公告)号：US5324659A
公开(公告)日：1994-06-28
申请号：US923082
申请日：1992-07-31
申请人： Stephen A. Parent , Leonardo E. Brizuela , Gary L. Chrebet , Keith A. Bostian
发明人： Stephen A. Parent , Leonardo E. Brizuela , Gary L. Chrebet , Keith A. Bostian
IPC分类号： C12N1/16 , C12N15/01 , C12Q1/02 , C12R1/865 , G01N33/50
CPC分类号： C12R1/85 , C12N15/01 , G01N33/5008 , Y10S435/942
摘要： Disclosed is a process utilizing yeast mutants for identifying active FK-506 type immunosuppressants. The process utilizes Saccharomyces cerevisiae mutants containing an fkr1, fkr2, fkr3 mutant gene or mixture thereof, which are resistant to FK-506 but sensitive to rapamycin. These mutants can be used in a diagnostic procedure for identifying FK-506 and FK-506 type immunosuppressants and in screening assays for compounds and fermentation broths which exhibit FK-506 type immunosuppressive activity. Specifically disclosed are the new yeast mutants, Saccharomyces cerevisiae YKF093, (Merck Culture Collection No. MY 2088) ATCC No. 74055, containing an fkr3 mutant gene, Saccharomyces cerevisiae YKF 012, (Merck Culture Collection No. MY 2096) ATCC No. 74061, which contains an fkr1 mutant gene, Saccharomyces cerevisiae YFK 014, (Merck Culture Collection No. MY 2097) ATCC No. 74062 and YFK-023-17A (Merck Culture Collection No. MY 2098) ATCC No. 74063, both which contain an fkr2 mutant gene and are useful in identifying active FK-506 type immunosuppressants.
摘要翻译：公开了利用酵母突变体鉴定活性FK-506型免疫抑制剂的方法。该方法利用含有fKr1，fkr2，fkr3突变基因或其混合物的酿酒酵母突变体，其对FK-506具有抗性，但对雷帕霉素敏感。这些突变体可用于鉴定FK-506和FK-506型免疫抑制剂的诊断程序，并用于展示FK-506型免疫抑制活性的化合物和发酵肉汤的筛选试验。具体公开的是含有fkr3突变基因，酿酒酵母YKF 012（Merck Culture Collection No. MY 2096）ATCC No.74061的新酵母突变体，酿酒酵母YKF093（Merck Culture Collection No. MY 2088）ATCC No.74055 ，其含有fkr1突变基因，酿酒酵母YFK 014（Merck Culture Collection No. MY 2097）ATCC No.74062和YFK-023-17A（Merck Culture Collection No. MY 2098）ATCC No.74063，它们都含有 fkr2突变基因，可用于鉴定活性FK-506型免疫抑制剂。

9. 发明申请

US20140329810A1 AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS 有权
标题翻译：用于改进药物动力学的气溶胶氟喹诺酮配方
公开(公告)号：US20140329810A1
公开(公告)日：2014-11-06
申请号：US14333583
申请日：2014-07-17
申请人： David C. GRIFFITH , Michael N. DUDLEY , Mark W. SURBER , Keith A. BOSTIAN , Olga RODNY
发明人： David C. GRIFFITH , Michael N. DUDLEY , Mark W. SURBER , Keith A. BOSTIAN , Olga RODNY
IPC分类号： A61K9/00 , A61K31/536
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
摘要翻译：本发明涉及抗微生物剂领域。特别地，本发明涉及用二价或三价阳离子配制的雾化氟喹诺酮类药物，并且具有改善的肺可用性，用于治疗和管理肺和上呼吸道的细菌感染。

10. 发明授权

US08815838B2 Aerosol fluoroquinolone formulations for improved pharmacokinetics 有权
标题翻译：气雾剂氟喹诺酮配方，用于改善药代动力学
公开(公告)号：US08815838B2
公开(公告)日：2014-08-26
申请号：US12574680
申请日：2009-10-06
申请人： David C. Griffith , Michael N. Dudley , Mark W. Surber , Keith A. Bostian , Olga Rodny
发明人： David C. Griffith , Michael N. Dudley , Mark W. Surber , Keith A. Bostian , Olga Rodny
IPC分类号： A61K31/397 , A61K31/535 , A61P11/06 , A61K31/47 , A61K47/02 , A61K31/4375 , A61K31/538 , A61K9/00
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
摘要翻译：本发明涉及抗微生物剂领域。特别地，本发明涉及用二价或三价阳离子配制的雾化氟喹诺酮类药物，并且具有改善的肺可用性，用于治疗和管理肺和上呼吸道的细菌感染。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式